RxDoctor Payments Data

Parveen Khanna, MD

Cardiovascular Disease · Manchester, CTNPI 1881689727

Payments from drug & device makers

$4,146in general payments, 2019–2025

Across 231 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$791
  • Amgen$239
  • AstraZeneca$212
  • E.r. Squibb & Sons, L.L.C.$205
  • Boehringer Ingelheim$201
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,09799%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,146 in reported general payments places this provider in the 65th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$424,897
Medicare patients
454
Services billed
3,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban466$657,701
XareltoRivaroxaban251$265,240
EntrestoSacubitril/Valsartan143$201,498
FarxigaDapagliflozin Propanediol136$162,827
JardianceEmpagliflozin52$79,043
Ranolazine ErRanolazine332$32,591
BrilintaTicagrelor28$31,253
Praluent PenAlirocumab20$25,507
Metoprolol Succinate1,543$20,049
DapagliflozinDapagliflozin Propanediol13$12,618
Amlodipine-ValsartanAmlodipine Besylate/Valsartan314$10,336
Valsartan306$7,638
Nebivolol Hcl106$6,997
Amlodipine Besylate898$5,123
Diltiazem 24hr Er (Cd)Diltiazem Hcl145$4,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$657,701466 claims
Johnson & JohnsonXarelto$1,347$265,240251 claims
NovartisEntresto$791$201,498143 claims
AstraZenecaFarxiga, Brilinta$212$194,080164 claims
Boehringer IngelheimJardiance$201$79,04352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Manchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →